Compare DTI & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTI | ATYR |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.7M | 79.2M |
| IPO Year | N/A | 2015 |
| Metric | DTI | ATYR |
|---|---|---|
| Price | $3.45 | $0.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 189.5K | ★ 1.9M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,964,000.00 | $190,000.00 |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $1.30 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $1.43 | $0.64 |
| 52 Week High | $3.82 | $7.29 |
| Indicator | DTI | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 43.87 |
| Support Level | $2.45 | $0.66 |
| Resistance Level | $3.42 | $0.74 |
| Average True Range (ATR) | 0.30 | 0.05 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 99.15 | 29.11 |
Drilling Tools International Corp manufactures, rents, inspects, and refurbishes downhole drilling tools primarily to companies in the oil and natural gas industry for bottom hole assemblies used in onshore and offshore horizontal and directional drilling. The company's United States operations have locations in Texas, California, Louisiana, Oklahoma, Pennsylvania, North Dakota, New Mexico, Utah, and Wyoming. The company's single segment derives revenues from customers by providing oilfield equipment and services to operators in the oil and natural gas sectors.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.